AKERO THERAPEUTICS INC. - COMMON STOCK

Akero Therapeutics Announces Positive End-of-Phase 2 Meeting with the FDA and SYNCHRONY Phase 3 Program for Efruxifermin in NASH

29 Mar 2023 16:01:00 By Nasdaq GlobeNewswire

Akero Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results

17 Mar 2023 07:00:00 By Nasdaq GlobeNewswire

Akero Therapeutics Appoints Patrick Lamy as Senior Vice President, Commercial Strategy

10 Jan 2023 08:00:01 By Nasdaq GlobeNewswire

Akero Therapeutics to Present at the 41st Annual J.P. Morgan Healthcare Conference

04 Jan 2023 08:00:01 By Nasdaq GlobeNewswire

Akero Therapeutics Completes Enrollment of Phase 2b SYMMETRY Study and Announces Expected 2023 Milestones

21 Dec 2022 16:01:00 By Nasdaq GlobeNewswire

Efruxifermin Granted FDA Breakthrough Therapy Designation for NASH

08 Dec 2022 07:00:00 By Nasdaq GlobeNewswire

Akero Therapeutics to Present at Upcoming Healthcare Conferences in November

10 Nov 2022 16:05:01 By Nasdaq GlobeNewswire

Akero Therapeutics to Present Late-Breaking Oral and Poster presentations on EFX Today at AASLD’s The Liver Meeting® 2022

07 Nov 2022 07:30:00 By Nasdaq GlobeNewswire

Akero Therapeutics to Present at the H.C. Wainwright 6th Annual NASH Investor Conference

11 Oct 2022 16:01:00 By Nasdaq GlobeNewswire

Akero Therapeutics Announces Closing of Upsized Public Offering of Common Stock and Full Exercise of Underwriters' Option to Purchase Additional Shares

19 Sep 2022 16:01:00 By Nasdaq GlobeNewswire

Akero Therapeutics Announces Pricing of Upsized Public Offering of Common Stock

14 Sep 2022 20:07:00 By Nasdaq GlobeNewswire

Akero Therapeutics Announces Proposed Public Offering of Common Stock

13 Sep 2022 16:01:00 By Nasdaq GlobeNewswire

In Akero Therapeutics’ Phase 2b HARMONY Study, Both the 50mg and 28mg EFX Doses Achieved Statistical Significance on Primary and Secondary Histology Endpoints after 24 Weeks

13 Sep 2022 06:00:00 By Nasdaq GlobeNewswire

Akero Therapeutics to Present Results from Phase 2b HARMONY Trial Investigating Efruxifermin in Patients with Pre-Cirrhotic NASH

08 Sep 2022 16:01:00 By Nasdaq GlobeNewswire

Study Published in JHEP Reports Shows Efruxifermin Rapidly Improved Fibrosis in Cirrhotic NASH patients After 16 Weeks of Treatment

24 Aug 2022 08:00:01 By Nasdaq GlobeNewswire

Akero Therapeutics Reports Second Quarter 2022 Financial Results and Provides Business Update

04 Aug 2022 16:05:37 By Nasdaq GlobeNewswire

Akero Therapeutics Presents Analysis at the 2022 International Liver Congress Showing that Efruxifermin Improved Histopathology and Markers of Liver Injury Across PNPLA3 Genotypes in Patients with NASH Fibrosis

27 Jun 2022 07:00:00 By Nasdaq GlobeNewswire

Akero Therapeutics Announces Two Financing Transactions with Pfizer Inc. and Hercules Capital, Inc. Providing Access to Up To $125 Million

16 Jun 2022 07:00:00 By Nasdaq GlobeNewswire

Akero Therapeutics to Present at Keystone Symposium on Efruxifermin as a Therapy for NASH

13 Jun 2022 08:00:01 By Nasdaq GlobeNewswire

Akero Therapeutics to Present at the Jefferies Global Healthcare Conference

01 Jun 2022 16:05:00 By Nasdaq GlobeNewswire